Verana Health announced the launch of Qdata Cataracts, which the company said, is the most comprehensive dataset available on cataract surgery outcomes. Derived from more than 9 million de-identified cataract surgery patients, with an average of nearly 4 years of follow-up, this research-ready dataset offers insights into patient demographics, clinical characteristics, and treatment pathways to support drug and treatment development, the company said in a press release.
Qdata Cataracts is powered by electronic health record (EHR) data from the American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight). The dataset includes key variables from unstructured clinician notes and semi-structured fields of EHRs that are extracted using proprietary artificial intelligence techniques. Those variables include visual acuity, intraocular pressure (IOP) reading, and intraocular lens (IOL) brand and model. A variable in development is femtosecond laser-assisted cataract surgery (FLACS). Qdata Cataracts provides critical real-world evidence (RWE) to inform clinical development, health economics and outcomes research (HEOR), and commercialization strategies, the company said in the press release.
“While cataract surgery is highly successful, real-world insights into surgical outcomes, lens selection, and patient experiences remain fragmented,” said Sujay Jadhav, CEO of Verana Health, in the press release. “Qdata Cataracts delivers a new level of clarity, equipping life sciences companies with high-quality evidence to advance clinical research, improve outcomes, reduce complications, and enhance intraocular lens technology.”
According to the company, Qdata Cataracts enables cohort identification, patient stratification, and real-world outcomes analysis that go beyond what claims data alone can provide. The dataset allows life sciences companies to evaluate post-surgical outcomes, patient responses to different IOL models, and treatment effectiveness in clinical practice. Qdata Cataracts supports a range of applications, including identifying practices treating cataract patients for clinical trial optimization, assessing treatment patterns and patient outcomes for HEOR initiatives, and refining market insights for commercialization efforts.
For more information on Qdata Cataracts and Verana Health’s Ophthalmology Qdata collection, visit: https://veranahealth.com/products/ophthalmology-qdata/.